NeuroPace (NPCE) Net Cash Flow (QoQ) (2020 - 2026)
NeuroPace (NPCE) Net Cash Flow (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn |
| 10 | NeuroPace | 478.49 Mn | 426.79 Mn | 18.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.87% |
| Mar 31, 2026 | -695.66% |
| Dec 31, 2025 | 147.25% |
| Sep 30, 2025 | 46.98% |
| Jun 30, 2025 | -130.54% |
| Mar 31, 2025 | 817.66% |
| Dec 31, 2024 | -174.86% |
| Sep 30, 2024 | 1,487.91% |
| Jun 30, 2024 | 96.38% |
| Mar 31, 2024 | -160.03% |
| Dec 31, 2023 | 349.68% |
| Sep 30, 2023 | 70.54% |
| Jun 30, 2023 | 850.43% |
| Mar 31, 2023 | -87.02% |
| Dec 31, 2022 | 2,431.43% |
| Sep 30, 2022 | 101.91% |
| Jun 30, 2022 | 84.37% |
| Mar 31, 2022 | -57.20% |
| Dec 31, 2021 | -61.38% |
| Sep 30, 2021 | -126.94% |